Ketamine vs Other Psychedelics: What Patients Should Know
Patients exploring psychedelic-assisted therapy often arrive with a mix of information from news articles, documentaries, and word of mouth. The result is a reasonable question: what actually makes ketamine different from psilocybin or MDMA, and why is one available at a clinic down the street while others require enrollment in a research trial? This post breaks down the practical differences.
How They Work Differently in the Brain
These substances are not variations on the same theme — they act through distinct mechanisms.
Ketamine primarily blocks NMDA receptors, which are glutamate receptors. This creates a dissociative state that can feel like detachment from the body or a dream-like altered perception. Ketamine also triggers downstream effects on BDNF (brain-derived neurotrophic factor) and synaptic plasticity that researchers believe contribute to its rapid antidepressant effects. The subjective experience typically lasts 45 minutes to an hour for IV administration.
Psilocybin (the active compound in “magic mushrooms”) is converted in the body to psilocin, which primarily activates serotonin 2A receptors. The experience is longer — typically 4 to 6 hours — and often involves visual phenomena, altered sense of time, and what many participants describe as a shift in perspective on their own thoughts and memories. Many clinical researchers believe the therapeutic mechanism involves this psychological experience, not just the pharmacology.
MDMA releases serotonin, dopamine, and norepinephrine and is classified as an entactogen — a substance that promotes feelings of emotional closeness and empathy. Its therapeutic use in clinical trials is specifically paired with psychotherapy sessions for PTSD, where the reduced fear response it produces may allow patients to process traumatic memories more effectively. Sessions are long (6-8 hours) and are conducted with two trained therapists present.
DMT (dimethyltryptamine), like psilocybin, acts on serotonin 2A receptors. Its effects when smoked or vaporized are extremely intense and brief (15-30 minutes). Clinical research into DMT-assisted therapy is early-stage. 5-MeO-DMT (found in certain toads and synthesized in labs) is related but distinct, with its own research programs underway.
Legal Status Side by Side
This comparison reflects the US federal and state landscape as of 2026:
| Substance | Federal Schedule | Clinical Availability |
|---|---|---|
| Ketamine (racemic) | Schedule III | Available at licensed clinics, off-label |
| Esketamine (Spravato) | Schedule III | FDA-approved for TRD at REMS-certified sites |
| Psilocybin | Schedule I | Oregon/Colorado licensed centers; clinical trials |
| MDMA | Schedule I | Clinical trials only (FDA CRL issued 2024) |
| DMT / 5-MeO-DMT | Schedule I | Research protocols only |
One important nuance: Schedule I does not mean a substance has no therapeutic value — it means the FDA has not yet approved it as a medical treatment. The scheduling of psilocybin and MDMA may change as clinical trial data accumulates and new drug applications are submitted. For current regulatory guidance, the DEA scheduling information page is the authoritative source.
What This Means If You Are Considering Treatment
The practical implication is that ketamine is the only widely accessible psychedelic treatment option at a conventional clinic today. If a clinic tells you they are offering psilocybin or MDMA therapy outside of a clinical trial setting, that is a significant red flag — those compounds are not legal to administer in a standard medical practice.
Oregon and Colorado psilocybin services are legal, but they operate under wellness-service frameworks rather than medical practice. They are not the same as a clinical trial or a physician-supervised treatment plan.
If your goal is to find a legal, supervised option available now, the pathway is:
- Talk to a psychiatrist about whether you meet criteria for treatment-resistant depression or another condition where ketamine is commonly used (ICD-10 codes F32.9 or F33.2 are the most common)
- Get a proper psychiatric evaluation (CPT 90791) before any infusions begin
- Choose a clinic where a licensed clinician supervises the sessions and integration support is available
If you are interested in psilocybin or MDMA research, ask your psychiatrist about active clinical trials, or search ClinicalTrials.gov for studies in your region.
A Note on “Psychedelic” Marketing
Some clinics use the language of psychedelic-assisted therapy loosely, applying it to ketamine infusions because ketamine does produce altered states. There is nothing wrong with this framing when it is honest. However, patients should understand that the evidence base, the experience, and the legal framework for ketamine are meaningfully different from those for psilocybin or MDMA in clinical trials.
Questions worth asking any provider: What training do your therapists have in integration? How do you handle challenging experiences during sessions? What is the follow-up protocol?
If you’d like guidance connecting with a verified provider, reach out here and we’ll help point you in the right direction.
This content is for educational purposes only and does not constitute medical advice. Consult a licensed clinician about your specific situation.
Drafted by AI and reviewed by our editorial team. Last updated 2026-05-30.